Kestra Medical Technologies (NASDAQ:KMTS - Free Report) had its price objective decreased by Wells Fargo & Company from $28.00 to $27.00 in a research note published on Thursday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.
KMTS has been the topic of a number of other research reports. The Goldman Sachs Group dropped their price target on shares of Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 16th. Wolfe Research began coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued an "outperform" rating and a $29.00 price target on the stock. Stifel Nicolaus began coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued a "buy" rating and a $28.00 price target on the stock. Piper Sandler began coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued an "overweight" rating and a $27.00 price target on the stock. Finally, Bank of America began coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued a "buy" rating and a $30.00 price target on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $27.33.
Get Our Latest Research Report on Kestra Medical Technologies
Kestra Medical Technologies Price Performance
Shares of NASDAQ KMTS traded down $0.56 during midday trading on Thursday, reaching $15.90. 860,676 shares of the stock were exchanged, compared to its average volume of 280,513. Kestra Medical Technologies has a twelve month low of $13.25 and a twelve month high of $26.15. The firm has a 50-day moving average price of $18.89.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its quarterly earnings data on Monday, April 14th. The company reported ($1.25) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.61). During the same period last year, the business earned ($1.18) EPS.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quarry LP purchased a new position in shares of Kestra Medical Technologies during the 1st quarter worth $33,000. Virtu Financial LLC purchased a new position in shares of Kestra Medical Technologies during the 1st quarter worth $210,000. Armistice Capital LLC purchased a new position in shares of Kestra Medical Technologies during the 1st quarter worth $312,000. Zimmer Partners LP purchased a new position in shares of Kestra Medical Technologies during the 1st quarter worth $374,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Kestra Medical Technologies during the 1st quarter worth $457,000.
Kestra Medical Technologies Company Profile
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Featured Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
